Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
86 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2014', provides an overview of the Allergic Rhino-Conjunctivitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Allergic Rhino-Conjunctivitis Overview 8 Therapeutics Development 9 Pipeline Products for Allergic Rhino-Conjunctivitis - Overview 9 Pipeline Products for Allergic Rhino-Conjunctivitis - Comparative Analysis 10 Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies 11 Allergic Rhino-Conjunctivitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Allergic Rhino-Conjunctivitis - Products under Development by Companies 15 Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 17 ALK-Abello A/S 17 Allergopharma Joachim Ganzer KG 18 Allergy Therapeutics plc 19 Anergis SA 20 Bial - Portela & Ca, S.A. 21 BioTech Tools s.a. 22 Circassia Pharmaceuticals plc 23 Greer Laboratories, Inc. 24 HAL Allergy BV 25 Immunomic Therapeutics, Inc. 26 Laboratorios LETI S.L. 27 Stallergenes S.A. 28 Allergic Rhino-Conjunctivitis - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 Acaroid - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AL-0704rP - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ALK Birch Pollen Vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Allergovac - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AllerT - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Avanz Phleum Pratense - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Depigoid Birch - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Dermatophagoides Pteronyssinus Allergen Extract - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 gpASIT + TM - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Grass Pollen Allergoid - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Grass-SPIRE - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 House Dust Mite-SPIRE - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 JRC-LAMP-Vax - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 MK-8237 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Olea Europaea Pollen Extract - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Pollinex Quattro Grass - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Ragweed Pollen Extract - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 rBet v1 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 rBet v1-FV - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 rPhleum - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Allergic Rhino-Conjunctivitis - Recent Pipeline Updates 69 Allergic Rhino-Conjunctivitis - Dormant Projects 77 Allergic Rhino-Conjunctivitis - Discontinued Products 78 Allergic Rhino-Conjunctivitis - Product Development Milestones 79 Featured News & Press Releases 79 Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 79 May 18, 2014: BioTech Tools will be present at the EAACI congress 80 Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 81 Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 82 Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 83 Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 83 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 86 Disclaimer 86
List of Tables Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2014 9 Number of Products under Development for Allergic Rhino-Conjunctivitis - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Development by Companies, H2 2014 (Contd..1) 16 Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2014 17 Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 18 Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics plc, H2 2014 19 Allergic Rhino-Conjunctivitis - Pipeline by Anergis SA, H2 2014 20 Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2014 21 Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2014 22 Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals plc, H2 2014 23 Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2014 24 Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2014 25 Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2014 26 Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2014 27 Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2014 28 Assessment by Monotherapy Products, H2 2014 29 Assessment by Combination Products, H2 2014 30 Number of Products by Stage and Target, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2014 69 Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2014 77 Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2014 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
